Clinical Trial Update: Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating weekly Copaxone vaccination for dry age-related macular degeneration has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Age-related Macular Degeneration

Drugs mentioned

• COPAXONE (GLATIRAMER ACETATE)

Snippet

Sponsor: The New York Eye & Ear Infirmary | Conditions: Dry Age Related Macular Degeneration | Phase 1 | Status: SUSPENDED